Early-stage lung adenocarcinoma (LUAD) exhibits substantial clinical heterogeneity that is not fully explained by TNM staging, highlighting the need for biology-driven prognostic tools. Although ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results